Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Leap Therapeutics Inc (LPTX)
NASDAQ:LPTX
Holding LPTX?
Track your performance easily
LPTX Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$1.32 - $5.00
Previous Close$3.55
Volume342.21K
Average Volume (3M)226.84K
Market Cap
$140.43M
Enterprise Value$62.43M
Total Cash (Recent Filing)$78.48M
Total Debt (Recent Filing)$482.00K
Price to Earnings (P/E)―
Beta1.90
Next Earnings
Nov 14, 2024EPS Estimate
-$0.49Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.00
Shares Outstanding38,264,464
10 Day Avg. Volume606,367
30 Day Avg. Volume226,837
Standard Deviation0.38
R-Squared0.00089
Alpha0.04
Financial Highlights & Ratios
Price to Book (P/B)2.16
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-2.50
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit10.00T>
Enterprise Value/Ebitda-0.95
Forecast
1Y Price Target
$7.25Price Target Upside95.42% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
Leap Therapeutics News
Ownership Overview
4.18% Insiders
3.31% Mutual Funds
3.67% Other Institutional Investors
83.72% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
LPTX FAQ
What was Leap Therapeutics Inc’s price range in the past 12 months?
Leap Therapeutics Inc lowest stock price was $1.32 and its highest was $5.00 in the past 12 months.
What is Leap Therapeutics Inc’s market cap?
Currently, no data Available
When is Leap Therapeutics Inc’s upcoming earnings report date?
Leap Therapeutics Inc’s upcoming earnings report date is Nov 14, 2024 which is in 4 days.
How were Leap Therapeutics Inc’s earnings last quarter?
Leap Therapeutics Inc released its earnings results on Aug 12, 2024. The company reported -$0.52 earnings per share for the quarter, missing the consensus estimate of -$0.42 by -$0.1.
Is Leap Therapeutics Inc overvalued?
According to Wall Street analysts Leap Therapeutics Inc’s price is currently Undervalued.
Does Leap Therapeutics Inc pay dividends?
Leap Therapeutics Inc does not currently pay dividends.
What is Leap Therapeutics Inc’s EPS estimate?
Leap Therapeutics Inc’s EPS estimate is -$0.49.
How many shares outstanding does Leap Therapeutics Inc have?
Leap Therapeutics Inc has 38,264,465 shares outstanding.
What happened to Leap Therapeutics Inc’s price movement after its last earnings report?
Leap Therapeutics Inc reported an EPS of -$0.52 in its last earnings report, missing expectations of -$0.42. Following the earnings report the stock price went down -3.252%.
Which hedge fund is a major shareholder of Leap Therapeutics Inc?
Among the largest hedge funds holding Leap Therapeutics Inc’s share is Baker Bros Advisors LP. It holds Leap Therapeutics Inc’s shares valued at 2M.
---
Leap Therapeutics Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$7.25 (95.42% Upside)
$7.25 (95.42% Upside)
Blogger Sentiment
Bullish
LPTX Sentiment 100%
Sector Average 72%
Sector Average 72%
Crowd Wisdom
Positive
Last 7 Days ▲ 3.7%
Last 30 Days ▼ 0.2%
Last 30 Days ▼ 0.2%
Technicals
SMA
Positive
20 days / 200 days
Momentum
96.13%
12-Months-Change
Fundamentals
Return on Equity
-80.23%
Trailing 12-Months
Asset Growth
-15.05%
Trailing 12-Months
Company Description
Leap Therapeutics Inc
Leap Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in developing novel therapies designed to treat patients with cancer. Its clinical stage programs are DKN-01 and TRX518. The company was founded on January 3, 2011 and is headquartered in Cambridge, MA.
---
LPTX Stock 12 Month Forecast
Average Price Target
$7.25
▲(95.42% Upside)
Technical Analysis
Adaptimmune Therapeutics
―
Fennec Pharmaceuticals
―
Cellectar Biosciences
―
Kazia Therapeutics
―
Best Analysts Covering LPTX
1 Year
1 Year Success Rate
6/20 ratings generated profit
1 Year Average Return
-20.93%
reiterated a buy rating 3 months ago
Copying Joel Beatty's trades and holding each position for 1 Year would result in 30.00% of your transactions generating a profit, with an average return of -20.93% per trade.
---